Drug intelligence / Profile preview

qirong fuzheng mixture

Development stage: Unknown
Lead developer: Shenzhen Third People's Hospital
Administration: Oral

Overview

Qirong Fuzheng Mixture is a Traditional Chinese Medicine (TCM) herbal formulation developed as an immunomodulatory therapy, particularly for patients with HIV/AIDS. The formulation typically contains extracts from *Astragalus membranaceus* (Huangqi) and *Cistanche deserticola* (Roucongrong), which are traditionally used to tonify "Qi" and "Yang" to strengthen the body's resistance (Fuzheng). In clinical settings, it is administered as an adjuvant to antiretroviral therapy (ART) to promote immune reconstitution, increase CD4+ T-lymphocyte counts, and improve the quality of life by reducing symptoms such as fatigue. The drug is currently being investigated in clinical trials sponsored by The Third People's Hospital of Shenzhen.

Other names: 芪茸扶正合剂Qirong Fuzheng Heji

Beyond the preview

Go deeper on qirong fuzheng mixture.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qirong fuzheng mixture.

Explore the full profile